Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post‐Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy
Cancer Medicine · 2025
DOI: 10.1002/cam4.71177 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Masayoshi Nagata und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945), Pfizer.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Avelumab maintenance therapy was approved in Japan for curatively unresectable urothelial carcinoma (UC) without progression after prior platinum‐based chemotherapy (PBC) based on results from the JAVELIN Bladder 100 phase 3 trial. We report post hoc analyses of post‐marketing surveillance (PMS) data in subgroups defined by age, prior PBC regimen, and best overall response (BOR) to prior PBC.
Methods
Patients with curatively unresectable UC who received ≥ 1 dose of avelumab maintenance in Japan between February and December 2021 were evaluated. The primary objective was to evaluate safety based on prespecified adverse drug reactions (ADRs). The secondary objective was to evaluate effectiveness, including time to treatment failure (TTF; discontinuation for any reason) and overall survival (OS).
Results
The analysis population included 453 patients. In patients aged ≤ 64 ( n = 75), 65 to 74 ( n = 198), or ≥ 75 ( n = 180) years, prespecified ADRs occurred in 17 (22.7%), 69 (34.9%), and 58 (32.2%); median TTF was 4.8, 4.4, and 4.9 months; and 12‐month OS rates were 77.6%, 82.7%, and 72.6%, respectively. In patients with prior cisplatin + gemcitabine ( n = 267), carboplatin + gemcitabine ( n = 163), or dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin ( n = 9) treatment, prespecified ADRs occurred in 93 (34.8%), 45 (27.6%), and 3 (33.3%); median TTF was 4.6, 4.6, and 5.1 months; and 12‐month OS rates were 79.6%, 73.8%, and 88.9%, respectively. In patients with prior complete response ( n = 47), partial response ( n = 242), or stable disease ( n = 149), prespecified ADRs occurred in 16 (34.0%), 79 (32.6%), and 45 (30.2%); median TTF was 5.2, 4.6, and 4.6 months; and 12‐month OS rates were 89.4%, 76.3%, and 75.8%, respectively.
Discussion
In this PMS population, safety and effectiveness were observed with avelumab maintenance therapy across subgroups defined by age, prior PBC regimen, or BOR to prior PBC. Findings support the favorable benefit–risk profile of avelumab maintenance in clinical practice. Trial Registration University Hospital Medical Information Network Clinical Trials Registry (UMIN‐CTR: UMIN 43435)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan.
- Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA, Darmstadt, Germany.
- Research & Development, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA, Darmstadt, Germany.
- Global Development Operations, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA, Darmstadt, Germany.
- Global Patient Safety Japan, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA, Darmstadt, Germany.
ORCID-Profile: Masayoshi Nagata
Förderung
- Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945)
- Pfizer
Zitieren
APA
Nagata, M., Kikuchi, E., Ito, T., Sato, M., Ogi, M., Morita, M., Kajita, M., & Nishiyama, H. (2025). Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post‐Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy. Cancer Medicine. https://doi.org/10.1002/cam4.71177
Vancouver
Nagata M, Kikuchi E, Ito T, Sato M, Ogi M, Morita M, et al. Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post‐Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy. Cancer Medicine. 2025. doi:10.1002/cam4.71177
BibTeX
@article{Nagata2025,
author = {Nagata, Masayoshi and Kikuchi, Eiji and Ito, Taito and Sato, Masashi and Ogi, Mie and Morita, Makiko and Kajita, Masahiro and Nishiyama, Hiroyuki},
title = {Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post‐Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71177}
}
EUVIMED